A biomarker is a biological marker that measures a biological state. It is used to denote normal biological and pathogenic processes for therapeutic intervention. These biomarkers can also be used in combination to access an individual’s medical condition. Scientists are further investigating structural and functional differences in neurological disorders. Additionally, a growing number of biobanks are helping to address unmet needs in oncology, neuroscience, and cardiovascular disease.
The University of British Columbia and the Karolinska Institute in Sweden have established a biobank to provide the resources and information needed for biomedical research. Alzheimer’s disease is the most common form of dementia affecting 12 million people. Neuroimaging and neuropsychological probes help predict Alzheimer’s disease before the behavioral test diagnoses it. Therefore, pre-evaluation tests such as positron emission tomography (PET) and functional magnetic resonance imaging (fMRI) are increasing the demand for neurological biomarkers.
Get Sample Copy of This Report @ https://www.persistencemarketresearch.com/samples/16303
Market segmentation:
based on image technology
- Transcranial Magnetic Stimulation (TMS)
- Diffusion tensor image (DTI)
- Conventional structural MRI (sMRI)
- Functional magnetic resonance imaging (fMRI)
- Positron Emission Tomography (PET)
Based on the application
- Proteomics-based biomarker
- genome-based biomarkers
- Imaging-based biomarkers
- metabolism-based biomarkers
based on indication
- Alzheimer’s disease (AD)
- multiple sclerosis (MS)
- Parkinson’s disease (PD)
- Autism Spectrum Disorder (ASD)
Based on end user
- hospital
- clinic
- Diagnostic and laboratory
based on service
- Sample preparation
- Assay development
- Biomarker validation and testing
For the full list of market players, request the table of contents here @ https://www.persistencemarketresearch.com/toc/16303
In terms of geography, the global neurological biomarkers market is segmented into five regions including North America, Asia Pacific & Middle East & Africa, Latin America & Europe. North America accounts for a large revenue share in the neurological biomarker industry due to the presence of many prominent market players in the region and the number of R&D projects conducted and government funding received by universities to conduct research. I’m here.
For example, in August 2015, researchers, patients, and various nonprofits participated in the Imaging Dementia-Amyloid Scan Evidence (IDEAS) study. The US $ 100 million project aims to study the usefulness of amyloid PET imaging for diagnosing dementia, Alzheimer’s disease, and cognitive impairment.
The Asia-Pacific region is the fastest growing region due to its huge population base, high incidence of neurological disorders, entry of new market players, and a huge aging population. In developing economies such as India and China, players in new industries are trying to establish their market presence by developing generic versions of biomarkers through contract research institutes. This has allowed us to further reduce the company’s manufacturing costs and other production-related costs.
Pre-book now for exclusive analyst support @ https://www.persistencemarketresearch.com/checkout/16303
Leading companies in the neurobiomarker industry are countless RBMs, Proteome Sciences, QIAGEN, Thermo Fisher Scientific, AbaStar MDx, Acumen Pharmaceuticals, Abiant, Aepodia, Athena Diagnostics, ImmunArray, Quantaix and CisbioBioassays.
About Us: Persistence Market Research
Contact us:
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City,
NY 10007 United States United
States Ph.D. – +1-646-568-7751
US-Canada Toll Free – +1 800-961-0353
Japan Office: 1-2-1 Kinshi Arca Central Building
14 / F Tokyo, 130-0013, Japan
Tel 1-888-863-3700
Sales – sales@persistencemarketresearch.com
Website – https://www.persistencemarketresearch.com